This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of NAZARE, et al.

Examiner:

Not Yet Known

Art Unit:

1624

Filed:

Application No.: 10/849,088

5/19/2004

TELEFAX CERTIFICATE

Title:

Indazole-derivatives as factor Xa

inhibitors

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313., P.O. Box 1450. Alexandria, VA 22313-1450. OIPE. at 703-746-4060, on

July 23, 2004

RESPONSE TO NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

Mail Stop Missing Parts Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

In response to the NOTICE TO FILE MISSING PARTS OF APPLICATION - FILING DATE GRANTED (hereinafter, "Notice") which was mailed on July 20, 2004, and which indicated that the oath or declaration is unsigned, Applicants submit herewith the Declarations for the present application, signed by inventors Marc NAZARE, Volkmar WEHNER, Volker LAUX, Matthias URMANN, Armin BAUER and Hans MATTER, along with a copy of the Notice.

Also enclosed is a Power of Attorney executed on behalf of Aventis Pharma Deutschland GmbH, with an effective date of June 29, 2004.

Please charge the \$130.00 surcharge required under 37 C.F.R. § 1.16(e) to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982.

Respectfully submitted

Jiang Lin, Reg. No. 51,065

Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4656
Telefax (908) 231-2626

JUL 2 3 2004

PADEMA

FAX TRANSMITTAL TO THE UNITED STATES PATENT OFFICE

Applicants Docket Number: CERTIFICATE OF TRANSMISSION I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, **DEAV2003/0032 US NP** VA 22313-1450, at 703-746-4060, on Applicants: Date of Deposit 7/23/2004 NAZARE, et al Printed Name of Person Signing Certificate Paul Irvine Signamire Serial No. 10/849,088 Total Number of Pages Sent: Jiang Lin Agent: Filing Date: May 19, 2004 1624 Group Art Unit: Unknown Examiner: Title of Invention: Indazole-derivatives as factor Xa Inhibitors

TO: Mail Stop Missing Parts
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

Amendment, 37 CFR		Fee Transmittal
Charge deposit account, in duplicate		Petition under 37 CFR
Extension of Time Petition		Other RESPONSE TO NOTICE TO FILE MISSING PARTS
Issue Fee Transmittal & Advance Order		Other <u>DECLARATION</u>
Maintenance Fee Transmittal	\boxtimes	Other POWER OF ATTORNEY
	\boxtimes	Other <u>COPY OF NOTICE TO FILE</u> <u>MISSING PARTS</u>

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entry named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT O

SP-1170

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

10/849-088

05/19/2004

Marc Nazare

Date Mailed: 07/20/2004

05487 ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC. **ROUTE 202-206** MAIL CODE: D303A BRIDGEWATER, NJ 08807

FORMALITIES LETTER *OC000000013279049*



NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is \$130 for a Large Entity

\$130 Late oath or declaration Surcharge.

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

07/27/2004 CNGUYEN 00000007 181982

10849088

01 FC:1051

130.00 DA

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

